Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
CC transcript
Appointed director
Inv. presentation
Appointed CFO
PDL BIOPHARMA, INC. (PDLI) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/14/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "PDL BioPharma Enters into $51.4 Million Capital Provision Agreement with Epps Investments LLC Regarding PDL’s Previously Announced Settlement Agreement with Wellstat"
12/08/2020 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Departure of Directors o...
Docs: "PDL Announces Timeline for Voluntarily Delisting from Nasdaq Expects to File a Certificate of Dissolution on January 4, 2021 Trading in PDL’s Common Stock on Nasdaq to be Suspended Prior to Market Opening on December 31, 2020"
10/07/2020 8-K Quarterly results
10/02/2020 8-K Quarterly results
09/10/2020 8-K Quarterly results
09/10/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "PDL BioPharma to Complete Spin-Off of LENSAR, Inc. on October 1, 2020 Declares Record Date of September 22, 2020 and Expected Share Distribution Date of October 1, 2020"
09/09/2020 8-K Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits  Interactive Data
Docs: "PDL BioPharma Completes Divestiture of the Noden Pharmaceutical Business to Stanley Capital"
08/31/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF CERTIFICATE OF AMENDMENT OF",
"Fourth Amended and Restated Bylaws of PDL BioPharma, Inc."
08/31/2020 8-K Quarterly results
08/28/2020 8-K Quarterly results
08/26/2020 8-K Quarterly results
08/20/2020 8-K Quarterly results
08/12/2020 8-K Quarterly results
08/06/2020 8-K Quarterly results
07/30/2020 8-K Quarterly results
07/28/2020 8-K Quarterly results
07/16/2020 8-K Quarterly results
06/29/2020 8-K Quarterly results
06/23/2020 8-K Quarterly results
05/21/2020 8-K Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
Docs: "PDL BioPharma Completes Distribution of Evofem Biosciences Common Stock to PDL Stockholders INCLINE VILLAGE, Nev. - PDL BioPharma, Inc. announces that it has completed its previously announced distribution of all of the Company’s 13,333,334 shares of common stock of Evofem Biosciences, Inc. , which represented approximately 26.7% of the outstanding shares of Evofem common stock as of the close of business on May 15, 2020 . The distribution was made today in the form of a pro rata common stock dividend to PDL stockholders of record as of the close of business on the record date. Based on the shares of PDL common stock outstanding as of the close of business on the record date, PDL stockholders of record as of the record date are entitled to receive 0.11591985 shares of Evofem common stock ..."
05/18/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "PDL BioPharma Declares Distribution Ratio for Dividend of Evofem Biosciences Common Stock to PDL Stockholders INCLINE VILLAGE, Nev. - PDL BioPharma, Inc. announces the final distribution ratio for the previously announced distribution of all of the Company’s 13,333,334 shares of common stock of Evofem Biosciences, Inc. to be made on May 21, 2020 . Based on the shares of PDL common stock outstanding as of the close of business on May 15, 2020 , PDL stockholders of record as of the record date will be entitled to receive 0.11591985 shares of Evofem common stock for each share of PDL common stock held as of the close of business on the record date. Subject to certain conditions, the distribution by PDL will be made on the distribution date in the form of a pro rata common stock dividend to ...",
"Information Statement"
05/07/2020 8-K Investor presentation, Quarterly results
Docs: "PDL BioPharma Reports 2020 First Quarter Financial Results Provides Update to Asset Monetization Plan Discusses Impact of COVID-19 on Operations and Monetization Plan - Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today - INCLINE VILLAGE, Nev. - PDL BioPharma, Inc. reports financial results for the three months ended March 31, 2020 and provides a business update: In March 2020, the Company announced that its Board of Directors approved a Plan of Complete Liquidation and passed a resolution to seek stockholder approval at its next Annual Meeting of Stockholders to dissolve the Company under Delaware state law in the event the Board concludes that the whole Company sale process is unlikely to maximize the value that can be returned to the stockholders. The Company has not se...",
"Presentation"
05/05/2020 8-K Quarterly results
05/04/2020 8-K Quarterly results
03/11/2020 8-K Quarterly results
03/09/2020 8-K Quarterly results
02/28/2020 8-K Quarterly results
01/15/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Presentation"
12/23/2019 8-K Quarterly results
12/19/2019 8-K Quarterly results
12/16/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "PDL BioPharma Board of Directors Increases Share and Note Repurchase Authorization to $275 Million"
12/13/2019 8-K Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "PDL BioPharma to Exchange Approximately 80% of Convertible Notes Due 2021 and 2024"
12/09/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "PDL BioPharma Announces Completion of Strategic Review Process Will Pursue Monetization of its Assets and Optimal Means of Returning Proceeds to Shareholders; Will Cease Making Additional Strategic Acquisitions and Investments Board Authorizes Repurchase Program to Acquire up to $200 Million of Outstanding PDL Stock and Convertible Notes Conference Call at 9:00 am Eastern Time Today"
11/18/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy